Category Candidate therapeutics Modality Manufacturer Status of clinical trials
Nucleoside Analogs
Pegylated interferon with ribavirin (Al-Tawfiq et al., 2014)
/
Valeant
Under clinical trial for COVID-19 (ChiCTR2000029387)
Favipiravir (T-705) (De Clercq, 2019) A guanine analog for the treatment of influenza virus infections Toyama Under clinical trial for COVID-19 (ChiCTR2000029548)
Remdesivir (Holshue et al., 2020) (GS-5734)
An adenine analog with a similar chemical structure to the approved HIV reverse transcriptase inhibitor tenofovir alafenamide.
Gilead
Phase II clinical trial for Ebola (NCT03719586); Under phase III clinical trials for COVID-19 (NCT04252664)
Type I interferons IFN-β1 (Sallard et al., 2020) Used as a treatment for multiple sclerosis Multiple companies Treatment of COVID-19 in the early stage
Protease inhibitors Lopinavir and ritonavir (Yamamoto et al., 2004) Protease inhibitors approved as anti-HIV drugs Abbott Under clinical trials for SARS; Under clinical trial for COVID-19 (ChiCTR2000029539)
Chloroquine Chloroquine and hydroxychloroquine (CDC, 2020) Oral prescription drugs for treatment of malaria and certain inflammatory conditions Multiple companies Under investigation in clinical trials for pre-exposure or post-exposure prophylaxis of SARS-CoV-2 infection
Antibodies CR3022 (Tian et al., 2020) A SARS Cov-specific human monoclonal antibody Multiple companies Experimental phase